{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:17:59Z","timestamp":1769915879883,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023961","name":"Centro de Investigaci\u00f3n Biotecnol\u00f3gica en Red de Enfermedades Infecciosas","doi-asserted-by":"publisher","award":["CB21\/13\/00077"],"award-info":[{"award-number":["CB21\/13\/00077"]}],"id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008441","name":"Ibero-American Program of Science and Technology for Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031692","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica","doi-asserted-by":"publisher","award":["CB06\/02\/0053"],"award-info":[{"award-number":["CB06\/02\/0053"]}],"id":[{"id":"10.13039\/100031692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jiph.2025.102827","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:18:16Z","timestamp":1747163896000},"page":"102827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of acquired resistance to antiretrovirals in children and adolescents living with HIV under clinical follow-up at the Roosevelt Hospital in Guatemala"],"prefix":"10.1016","volume":"18","author":[{"given":"S.","family":"Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Navas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Or\u00f3zco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"G\u00f3mez-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Medina-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Holgu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2025.102827_bib1","unstructured":"UNAIDS Data 2023; 2023. \u3008https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/2023_unaids_data\u3009 [Accessed 9 January 2024]."},{"issue":"21","key":"10.1016\/j.jiph.2025.102827_bib2","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants","volume":"359","author":"Violari","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2025.102827_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/QAI.0000000000002366","article-title":"Challenges in the early infant HIV diagnosis and treatment cascade","volume":"84","author":"Mofenson","year":"2020","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiph.2025.102827_bib4","unstructured":"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection; 2024. \u3008https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv\u3009 [Accessed 11 June 2024]."},{"issue":"1","key":"10.1016\/j.jiph.2025.102827_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/QAI.0000000000000671","article-title":"HIV-1 drug resistance and second-line treatment in children randomized to switch at low versus higher RNA thresholds","volume":"70","author":"Harrison","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.jiph.2025.102827_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30252-6","article-title":"Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey","volume":"7","author":"Hemelaar","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2025.102827_bib7","unstructured":"Global action plan on HIV Drug resistance 2017-2021; 2017. \u3008https:\/\/www.who.int\/publications\/i\/item\/978-92-4-151284-8\u3009 [Accessed 11 June 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib8","unstructured":"UNAIDS Data 2023. Regional Factsheet: Latin America; 2023. \u3008https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023\/assets\/files\/regional_fs_latin_america.pdf\u3009 [Accessed 9 January 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib9","unstructured":"UNAIDS Data 2023. Guatemala Data; 2023. \u3008https:\/\/www.unaids.org\/en\/regionscountries\/countries\/guatemala\u3009; [Accessed 9 January 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib10","unstructured":"Programa Nacional de Prevenci\u00f3n y Control de ITS, VIH y Sida. Ministerio de Salud P\u00fablica y Asistencia Social de Guatemala; 2022. \u3008https:\/\/programavihguatemala.com\/programa-vih\/\u3009 [Accessed 9 January 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib11","unstructured":"Vigilancia Epidemiol\u00f3gica del VIH Guatemala enero-mayo 2023. Ministerio de Salud P\u00fablica y Asistencia Social de Guatemala; 2023. \u3008https:\/\/epidemiologia.mspas.gob.gt\/informacion\/vigilancia-epidemiologica\/salas-situacionales\/12-vih\u3009. [Accessed 14 February 2024]."},{"issue":"4","key":"10.1016\/j.jiph.2025.102827_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/aid.2014.0057","article-title":"HIV-1 drug resistance surveillance in antiretroviral treatment-naive individuals from a reference hospital in Guatemala, 2010-2013","volume":"31","author":"Avila-R\u00edos","year":"2015","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"10.1016\/j.jiph.2025.102827_bib13","article-title":"Resistencia transmitida de VIH-1 en pacientes sin exposici\u00f3n a tratamiento antirretroviral","volume":"11","author":"Navas Castillo","year":"2024","journal-title":"Guatem Fac Med (Univ Rep\u00fab Urug)"},{"issue":"6","key":"10.1016\/j.jiph.2025.102827_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.4067\/S0716-10182013000600010","volume":"30","author":"Mendiz\u00e1bal-Burastero","year":"2013","journal-title":"Rev Chil Infectol"},{"issue":"92","key":"10.1016\/j.jiph.2025.102827_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.22533\/at.ed.1593922308114","article-title":"Resistencia del VIH-1 a f\u00e1rmacos antirretrovirales en pacientes adultos con fallo virol\u00f3gico. Hospital Roosevelt, Guatemala","volume":"3","author":"Navas Castillo","year":"2023","journal-title":"Int J Health Sci"},{"key":"10.1016\/j.jiph.2025.102827_bib16","unstructured":"Gu\u00eda de tratamiento antirretroviral e infecciones oportunistas en Guatemala. Ministerio de Salud P\u00fablica y Asistencia Social de Guatemala; 2013. \u3008https:\/\/www.mcr-comisca.org\/guatemala\/767-guia-de-tratamiento-antirretroviral-y-de-infecciones-oportunistas-en-guatemala-2013\/file\u3009 [Accessed 3 June 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib17","unstructured":"Programa Nacional de Prevenci\u00f3n y Control de ITS, VIH y Sida Unidad de Monitoreo y Evaluaci\u00f3n. Ministerio de Salud P\u00fablica y Asistencia Social de Guatemala; 2022. \u3008https:\/\/programavihguatemala.com\/\u3009 [Accessed 9 January 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib18","unstructured":"Data reported to the National Program for the Prevention and Control of STIs, HIV and AIDS Guatemala. 2023. Data generated by the Comprehensive HIV and Chronic Infections Care unit \u201cDr. Carlos Rodolfo Mej\u00eda Villatoro\u201d, Roosevelt Hospital."},{"issue":"10","key":"10.1016\/j.jiph.2025.102827_bib19","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1016\/S2352-3018(23)00173-X","article-title":"Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use","volume":"10","author":"Mbuagbaw","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2025.102827_bib20","unstructured":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. WHO definitions of clinical, immunological and virological failure for the decision to switch ART regimens; 2021. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572730\/table\/ch4.table11\/\u3009 [Accessed 10 January 2024]."},{"issue":"5","key":"10.1016\/j.jiph.2025.102827_bib21","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/INF.0b013e3182117289","article-title":"Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in honduras and el salvador during 1989-2009","volume":"30","author":"Holgu\u00edn","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.jiph.2025.102827_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1089\/aid.2015.0122","article-title":"Analysis of reverse transcriptase and protease genes of HIV for antiretroviral drug resistance in treatment-exposed Jamaican pediatrics","volume":"31","author":"Ramkissoon","year":"2015","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"10.1016\/j.jiph.2025.102827_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12519-022-00554-0","article-title":"Retrospective study of HIV drug resistance in Mexican children with vertically transmitted infection","volume":"18","author":"de Jes\u00fas Herrera-Castillo","year":"2022","journal-title":"World J Pediatr"},{"issue":"2","key":"10.1016\/j.jiph.2025.102827_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/jac\/dkac407","article-title":"Drug resistance in children and adolescents with HIV in Panama","volume":"78","author":"Ventosa-Cubillo","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jiph.2025.102827_bib25","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkac138","article-title":"HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): Results from a cohort study in Argentina","volume":"77","author":"Rozenszajn","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2025.102827_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(11)60208-0","article-title":"Risk of triple-class virological failure in children with HIV: a retrospective cohort study","volume":"377","author":"Judd","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2025.102827_bib27","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/QAD.0000000000000316","article-title":"Adherence to antiretroviral therapy in adolescents living with HIV: systemic review and meta-analysis","volume":"28","author":"Kim","year":"2014","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jiph.2025.102827_bib28","doi-asserted-by":"crossref","first-page":"605.e1-e9","DOI":"10.1016\/j.cmi.2015.02.003","article-title":"Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses","volume":"21","author":"Rojas S\u00e1nchez","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jiph.2025.102827_bib29","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","volume":"11","author":"Gaur","year":"2024","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.jiph.2025.102827_bib30","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S2214-109X(21)00025-5","article-title":"The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis","volume":"9","author":"Phillips","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.jiph.2025.102827_bib31","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiph.2025.102827_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jiph.2025.102827_bib33","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.jiph.2025.102827_bib34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.jiph.2025.102827_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.jiph.2025.102827_bib36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2025.102827_bib37","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2352-3018(24)00155-3","article-title":"Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial","volume":"12","author":"White","year":"2025","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.jiph.2025.102827_bib38","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2025.102827_bib39","unstructured":"Paediatric DTG implementation considerations for national programmes; 2022. \u3008https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/2022gapfdtgguidance_english.pdf?sfvrsn=c12f257d_10&download=true\u3009 [Accessed 15 February 2024]."},{"key":"10.1016\/j.jiph.2025.102827_bib40","unstructured":"Bello G., Pals S., Bighignoli B., Kabaghe A., Mkungudza J., Panje L., Emerging dolutegravir resistance among children being investigated for treatment failure in Malawi. Presented at conference on retroviruses and opportunistic infections. Denver, CO, USA. Abstract 187; 2024."}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125001765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125001765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:52:56Z","timestamp":1762559576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125001765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1876034125001765"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102827","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of acquired resistance to antiretrovirals in children and adolescents living with HIV under clinical follow-up at the Roosevelt Hospital in Guatemala","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102827"}}